VIRGINIA RETIREMENT SYSTEMS ET Al Buys 34,000 Shares of Denali Therapeutics Inc. $DNLI

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 237.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,300 shares of the company’s stock after acquiring an additional 34,000 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Denali Therapeutics were worth $998,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in shares of Denali Therapeutics by 44.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock valued at $46,000 after purchasing an additional 687 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Denali Therapeutics by 8.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock worth $177,000 after purchasing an additional 739 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $26,000. Global Retirement Partners LLC bought a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $28,000. Finally, Nykredit A S bought a new position in shares of Denali Therapeutics during the 2nd quarter valued at approximately $38,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $19.72 on Friday. Denali Therapeutics Inc. has a 1-year low of $13.75 and a 1-year high of $27.30. The company has a 50-day moving average of $20.25 and a 200 day moving average of $21.26. The company has a current ratio of 6.21, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.64. The company had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $12.67 million. During the same period last year, the firm earned ($0.74) earnings per share. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.70 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 9.70% of the stock is currently owned by company insiders.

Trending Headlines about Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali reported Q3 revenue of $17.78 million, above the $12.67 million consensus, and EPS of $0.37 versus analysts’ expected loss of $0.27. Avlayah sales rose nearly fivefold, reimbursement coverage expanded, and the company cited upcoming pipeline catalysts—factors supporting the reported post-earnings rally. Article: DNLI Up 7.8% Post Q3 Earnings
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an overweight rating; Wedbush raised its target to $24 and reiterated outperform. BTIG also reaffirmed its buy rating with a $39 target, reinforcing favorable analyst sentiment. Morgan Stanley rating information Wedbush rating information BTIG rating information
• Neutral Sentiment: HC Wainwright’s quarterly forecasts project ongoing losses in 2027, ranging from $0.60 per share in Q1 to $0.53 in Q4. These are analyst estimates, not company guidance; the current-year consensus cited in the reports is a loss of $2.70 per share. MarketBeat Denali coverage

Analyst Ratings Changes

Several analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their price objective on shares of Denali Therapeutics from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft increased their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a report on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $36.15.

Denali Therapeutics Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.